FindTrial
Sign In

NPB-01

DRUG7 trials

Sponsors

Nihon Pharmaceutical Co., Ltd

Conditions

Autoimmune EncephalitisBullous PemphigoidChronic Inflammatory Demyelinating PolyneuropathyGuillain-Barré SyndromeMultifocal Motor NeuropathyNeuromyelitis Optica Spectrum Disorder

Phase 2

Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.
CompletedNCT00809822
Nihon Pharmaceutical Co., LtdBullous Pemphigoid
Start: 2008-11-30End: 2010-10-31Target: 20Updated: 2010-10-25
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
CompletedNCT01845584
Nihon Pharmaceutical Co., LtdNeuromyelitis Optica Spectrum Disorder
Start: 2013-05-31End: 2015-08-31Updated: 2017-04-12

Phase 3

Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids
CompletedNCT01408550
Nihon Pharmaceutical Co., LtdBullous Pemphigoid
Start: 2011-08-31End: 2013-09-30Target: 56Updated: 2013-10-16
Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
CompletedNCT01824251
Nihon Pharmaceutical Co., LtdChronic Inflammatory Demyelinating Polyneuropathy
Start: 2013-04-30End: 2015-09-30Updated: 2016-01-20
Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.
CompletedNCT01827072
Nihon Pharmaceutical Co., LtdMultifocal Motor Neuropathy
Start: 2013-04-30End: 2015-06-30Updated: 2016-01-20
Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome
CompletedNCT02221271
Nihon Pharmaceutical Co., LtdGuillain-Barré Syndrome
Start: 2014-10-31End: 2015-08-31Updated: 2017-04-12
Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis
NCT05177939
Nihon Pharmaceutical Co., LtdAutoimmune Encephalitis
Start: 2022-03-03End: 2024-10-31Target: 40Updated: 2022-12-01

Related Papers

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
Frontiers in Neurology2024-08-1314 citations
Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi‐center, open‐label, 52‐week phase 3 trial
Journal of the Peripheral Nervous System2018-04-1012 citations
Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial
Journal of Neurology Neurosurgery & Psychiatry2017-08-0252 citations